Logo

PHG

Koninklijke Philips N.V.

PHG

Koninklijke Philips N.V. • NYSE
$28.16 ▲ 0.32% (+0.09)
Market Cap $26.78 B
52w High $29.54
52w Low $21.48
Dividend Yield 0.89%
P/E 148.21
Volume 234.84K
Outstanding Shares 950.98M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $4.302B ▼ $1.58B ▼ $184M ▼ 4.277% ▼ $0.19 ▼ $635M ▼
Q2-2025 $4.338B ▲ $1.611B ▼ $240M ▲ 5.533% ▲ $0.25 ▲ $683M ▲
Q1-2025 $4.097B ▼ $1.695B ▼ $76M ▲ 1.855% ▲ $0.08 ▲ $462M ▼
Q4-2024 $5.044B ▲ $1.764B ▲ $-335M ▼ -6.642% ▼ $-0.36 ▼ $545.5M ▲
Q3-2024 $4.377B $1.669B $181M 4.135% $0.2 $351M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.912B ▲ $26.339B ▼ $15.756B ▼ $10.552B ▲
Q2-2025 $1.824B ▲ $26.379B ▼ $15.971B ▲ $10.379B ▼
Q1-2025 $1.195B ▼ $27.167B ▼ $15.439B ▼ $11.697B ▼
Q4-2024 $2.403B ▲ $28.976B ▲ $16.933B ▲ $12.006B ▲
Q3-2024 $1.813B $0 $-11.919B $11.919B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $184M ▼ $327M ▼ $-158M ▲ $-68M ▼ $90M ▼ $259M ▲
Q2-2025 $242M ▲ $387M ▲ $-225M ▼ $546M ▲ $629M ▲ $228M ▲
Q1-2025 $86.302M ▲ $-981.948M ▼ $-175.761M ▼ $-50.518M ▼ $-1.04B ▼ $-1.04B ▼
Q4-2024 $-335M ▼ $0 $0 $0 $0 $0
Q3-2024 $181M $0 $0 $0 $0 $0

Five-Year Company Overview

Income Statement

Income Statement Philips’ sales have been fairly steady over the last few years, but profitability has been volatile. The company moved from healthy profits earlier in the period to sizable losses, mainly due to one‑off issues, restructuring, and legacy product and recall costs. Underlying operating performance has improved recently, with the core business drifting back into profit, but overall net results are still negative. In simple terms, the top line is holding up, margins are slowly healing, yet the bottom line is not fully repaired and remains a key watch‑point.

Balance Sheet

Balance Sheet The balance sheet looks solid but not pristine. Total assets and shareholder equity have been relatively stable, suggesting no extreme financial stress, though equity is lower than a few years ago. Debt remains meaningful but manageable, and recent growth in cash balances improves flexibility and cushions shocks. Overall, Philips appears to have a reasonable financial foundation, but not an overly conservative one, so consistent earnings recovery will matter for maintaining balance sheet strength.

Cash Flow

Cash Flow Cash generation tells a more encouraging story than reported earnings. After a weak patch when operating cash flow turned negative, Philips has returned to producing solid cash from its core activities for two years in a row. Free cash flow is again comfortably positive even after ongoing investment in equipment and technology. This suggests the underlying business is healthier than the recent net losses might imply, provided this stronger cash performance can be sustained.

Competitive Edge

Competitive Edge Philips holds a strong position in hospital imaging, monitoring, and image‑guided therapy, with deep relationships across global healthcare systems. Its installed base of equipment, bundled software, and long‑term service contracts create high switching costs for customers. The company competes with powerful rivals like GE Healthcare and Siemens Healthineers, but differentiates through a more integrated, patient‑centric platform and a strong focus on cardiology and connected care. Product quality issues and recalls in recent years have, however, hurt reputation and profitability, so rebuilding trust and execution discipline is strategically critical.

Innovation and R&D

Innovation and R&D Innovation is a clear strength. Philips consistently invests heavily in research and development, focusing on AI‑enabled imaging, digital health platforms, and more sustainable technologies such as helium‑free MRI systems. Its cloud‑based HealthSuite ecosystem, AI Orchestrator, and telehealth and enterprise imaging offerings position the company well for the shift toward data‑driven, connected care. The pipeline in image‑guided therapy and precision diagnosis looks robust, but the value of this innovation will depend on smooth product launches, regulatory success, and commercial adoption by hospitals under budget pressure.

Summary

Philips is a health‑tech company in transition: operationally recovering, financially still cleaning up past problems, and strategically well placed in attractive healthcare niches. Revenue is stable and cash flow has improved, but net income remains dragged down by legacy issues and restructuring. The balance sheet is reasonably sound with adequate liquidity and moderate leverage. Competitively, Philips benefits from a large installed base, strong brand, and deep clinical integration, but faces intense rivals and reputational repair work. Its heavy commitment to AI, digital platforms, and sustainable medical technology offers meaningful long‑term opportunity, with execution quality and legal/recall overhangs as the main risks to monitor.

NEWS

November 24, 2025 · 9:00 AM UTC

Philips launches next-generation web-based diagnostic viewer for fast, secure imaging data access anywhere

Read more

November 19, 2025 · 9:00 AM UTC

Philips and Cortechs.ai extend partnership to advance quantitative neuroimaging and strengthen Philips' leadership in precision diagnostics in neurology

Read more

November 17, 2025 · 8:00 AM UTC

Philips brings AI into the procedure room to assist doctors during heart valve repair

Read more

November 4, 2025 · 1:00 AM UTC

Philips continues momentum; delivers strong order intake, step-up in sales growth and margin expansion

Read more

November 3, 2025 · 8:30 AM UTC

Philips Joins the Forever Promise Project to Honor American Veterans

Read more